S&P 500   2,954.22 (-0.82%)
DOW   25,409.36 (-1.39%)
QQQ   205.80 (+0.08%)
AAPL   273.36 (-0.06%)
FB   192.47 (+1.43%)
GOOGL   1,339.25 (+1.85%)
AMZN   1,883.75 (-0.03%)
NVDA   270.07 (+6.92%)
BABA   208.00 (+1.45%)
MU   52.56 (+3.91%)
GE   10.88 (+4.72%)
TSLA   667.99 (-1.62%)
AMD   45.48 (+3.34%)
ACB   1.34 (-7.59%)
F   6.96 (-0.14%)
BAC   28.50 (-2.16%)
GILD   69.36 (-4.54%)
DIS   117.65 (-0.33%)
S&P 500   2,954.22 (-0.82%)
DOW   25,409.36 (-1.39%)
QQQ   205.80 (+0.08%)
AAPL   273.36 (-0.06%)
FB   192.47 (+1.43%)
GOOGL   1,339.25 (+1.85%)
AMZN   1,883.75 (-0.03%)
NVDA   270.07 (+6.92%)
BABA   208.00 (+1.45%)
MU   52.56 (+3.91%)
GE   10.88 (+4.72%)
TSLA   667.99 (-1.62%)
AMD   45.48 (+3.34%)
ACB   1.34 (-7.59%)
F   6.96 (-0.14%)
BAC   28.50 (-2.16%)
GILD   69.36 (-4.54%)
DIS   117.65 (-0.33%)
S&P 500   2,954.22 (-0.82%)
DOW   25,409.36 (-1.39%)
QQQ   205.80 (+0.08%)
AAPL   273.36 (-0.06%)
FB   192.47 (+1.43%)
GOOGL   1,339.25 (+1.85%)
AMZN   1,883.75 (-0.03%)
NVDA   270.07 (+6.92%)
BABA   208.00 (+1.45%)
MU   52.56 (+3.91%)
GE   10.88 (+4.72%)
TSLA   667.99 (-1.62%)
AMD   45.48 (+3.34%)
ACB   1.34 (-7.59%)
F   6.96 (-0.14%)
BAC   28.50 (-2.16%)
GILD   69.36 (-4.54%)
DIS   117.65 (-0.33%)
S&P 500   2,954.22 (-0.82%)
DOW   25,409.36 (-1.39%)
QQQ   205.80 (+0.08%)
AAPL   273.36 (-0.06%)
FB   192.47 (+1.43%)
GOOGL   1,339.25 (+1.85%)
AMZN   1,883.75 (-0.03%)
NVDA   270.07 (+6.92%)
BABA   208.00 (+1.45%)
MU   52.56 (+3.91%)
GE   10.88 (+4.72%)
TSLA   667.99 (-1.62%)
AMD   45.48 (+3.34%)
ACB   1.34 (-7.59%)
F   6.96 (-0.14%)
BAC   28.50 (-2.16%)
GILD   69.36 (-4.54%)
DIS   117.65 (-0.33%)
Log in

NYSE:ABT - Abbott Laboratories Stock Price, Forecast & News

$77.04
-2.15 (-2.71 %)
(As of 02/28/2020 04:00 PM ET)
Today's Range
$74.02
Now: $77.04
$78.06
50-Day Range
$81.13
MA: $88.03
$91.86
52-Week Range
$72.36
Now: $77.04
$92.45
Volume1.85 million shs
Average Volume4.40 million shs
Market Capitalization$135.85 billion
P/E Ratio37.40
Dividend Yield1.77%
Beta1.13
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryHealth Care Equipment
SectorMedical
CUSIP00282410
CIK1800
Phone224-667-6100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$31.90 billion
Cash Flow$4.72 per share
Book Value$17.75 per share

Profitability

Net Income$3.69 billion

Miscellaneous

Employees103,000
Outstanding Shares1,763,430,000
Market Cap$135.85 billion
Next Earnings Date4/15/2020 (Estimated)
OptionableOptionable

Receive ABT News and Ratings via Email

Sign-up to receive the latest news and ratings for ABT and its competitors with MarketBeat's FREE daily newsletter.


Abbott Laboratories (NYSE:ABT) Frequently Asked Questions

What is Abbott Laboratories' stock symbol?

Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."

How often does Abbott Laboratories pay dividends? What is the dividend yield for Abbott Laboratories?

Abbott Laboratories announced a quarterly dividend on Friday, February 21st. Shareholders of record on Wednesday, April 15th will be given a dividend of $0.36 per share on Friday, May 15th. This represents a $1.44 dividend on an annualized basis and a dividend yield of 1.87%. The ex-dividend date is Tuesday, April 14th. This is an increase from Abbott Laboratories's previous quarterly dividend of $0.08. View Abbott Laboratories' Dividend History.

How were Abbott Laboratories' earnings last quarter?

Abbott Laboratories (NYSE:ABT) issued its earnings results on Wednesday, January, 22nd. The healthcare product maker reported $0.95 earnings per share for the quarter, hitting the Thomson Reuters' consensus estimate of $0.95. The healthcare product maker earned $8.31 billion during the quarter, compared to analysts' expectations of $8.26 billion. Abbott Laboratories had a net margin of 11.56% and a return on equity of 18.39%. The company's revenue was up 7.1% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.81 EPS. View Abbott Laboratories' Earnings History.

When is Abbott Laboratories' next earnings date?

Abbott Laboratories is scheduled to release their next quarterly earnings announcement on Wednesday, April 15th 2020. View Earnings Estimates for Abbott Laboratories.

What guidance has Abbott Laboratories issued on next quarter's earnings?

Abbott Laboratories issued an update on its FY20 earnings guidance on Wednesday, January, 22nd. The company provided earnings per share guidance of $3.55-3.65 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.60.

What price target have analysts set for ABT?

18 brokerages have issued 12-month target prices for Abbott Laboratories' stock. Their forecasts range from $81.00 to $105.00. On average, they anticipate Abbott Laboratories' stock price to reach $95.79 in the next year. This suggests a possible upside of 24.3% from the stock's current price. View Analyst Price Targets for Abbott Laboratories.

What is the consensus analysts' recommendation for Abbott Laboratories?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last year. There are currently 2 sell ratings, 4 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Abbott Laboratories.

Has Abbott Laboratories been receiving favorable news coverage?

Media headlines about ABT stock have been trending somewhat negative this week, InfoTrie reports. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Abbott Laboratories earned a media sentiment score of -1.0 on InfoTrie's scale. They also gave news articles about the healthcare product maker a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Abbott Laboratories.

Who are some of Abbott Laboratories' key competitors?

What other stocks do shareholders of Abbott Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Abbott Laboratories investors own include AbbVie (ABBV), AT&T (T), Cisco Systems (CSCO), Johnson & Johnson (JNJ), Home Depot (HD), NVIDIA (NVDA), Walt Disney (DIS), Verizon Communications (VZ), Pfizer (PFE) and Intel (INTC).

Who are Abbott Laboratories' key executives?

Abbott Laboratories' management team includes the folowing people:
  • Mr. Miles D. White M.B.A., Chairman & CEO (Age 64)
  • Mr. Robert B. Ford, Pres & COO (Age 45)
  • Mr. Brian B. Yoor, Exec. VP of Fin. & CFO (Age 49)
  • Mr. Hubert L. Allen, Exec. VP, Gen. Counsel & Sec. (Age 53)
  • Mr. Stephen R. Fussell, Exec. VP of HR (Age 62)

Who are Abbott Laboratories' major shareholders?

Abbott Laboratories' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Capital Research Global Investors (6.43%), State Street Corp (4.16%), Capital International Investors (2.68%), Massachusetts Financial Services Co. MA (1.75%), Geode Capital Management LLC (1.41%) and FMR LLC (1.41%). Company insiders that own Abbott Laboratories stock include Andrea F Wainer, Andrew H Lane, Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Hubert L Allen, Jaime Contreras, Jared Watkin, John G Stratton, John M Capek, Joseph J Manning, Mary K Moreland, Michael D Dale, Michael J Pederson, Miles D White, Randel William Woodgrift, Roger Bird, Sally E Blount, Sharon J Bracken and Stephen R Fussell. View Institutional Ownership Trends for Abbott Laboratories.

Which major investors are selling Abbott Laboratories stock?

ABT stock was sold by a variety of institutional investors in the last quarter, including Fred Alger Management LLC, FIL Ltd, FMR LLC, Thrivent Financial for Lutherans, Janus Henderson Group PLC, Massachusetts Financial Services Co. MA, Bank of New York Mellon Corp and UBS Asset Management Americas Inc.. Company insiders that have sold Abbott Laboratories company stock in the last year include Andrea F Wainer, Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Hubert L Allen, Jaime Contreras, Jared Watkin, John M Capek, Joseph J Manning, Mary K Moreland, Michael D Dale, Michael J Pederson, Miles D White, Randel William Woodgrift, Roger Bird, Sally E Blount, Sharon J Bracken and Stephen R Fussell. View Insider Buying and Selling for Abbott Laboratories.

Which major investors are buying Abbott Laboratories stock?

ABT stock was acquired by a variety of institutional investors in the last quarter, including Polen Capital Management LLC, Wealth Quarterback LLC, Capital International Investors, Macquarie Group Ltd., State Street Corp, GQG Partners LLC, Capital Research Global Investors and Alliancebernstein L.P.. Company insiders that have bought Abbott Laboratories stock in the last two years include John G Stratton and Randel William Woodgrift. View Insider Buying and Selling for Abbott Laboratories.

How do I buy shares of Abbott Laboratories?

Shares of ABT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Abbott Laboratories' stock price today?

One share of ABT stock can currently be purchased for approximately $77.04.

How big of a company is Abbott Laboratories?

Abbott Laboratories has a market capitalization of $135.85 billion and generates $31.90 billion in revenue each year. The healthcare product maker earns $3.69 billion in net income (profit) each year or $3.24 on an earnings per share basis. Abbott Laboratories employs 103,000 workers across the globe.View Additional Information About Abbott Laboratories.

What is Abbott Laboratories' official website?

The official website for Abbott Laboratories is http://www.abbott.com/.

How can I contact Abbott Laboratories?

Abbott Laboratories' mailing address is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. The healthcare product maker can be reached via phone at 224-667-6100.


MarketBeat Community Rating for Abbott Laboratories (NYSE ABT)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  790 (Vote Outperform)
Underperform Votes:  666 (Vote Underperform)
Total Votes:  1,456
MarketBeat's community ratings are surveys of what our community members think about Abbott Laboratories and other stocks. Vote "Outperform" if you believe ABT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/28/2020 by MarketBeat.com Staff

Featured Article: P/E Growth (PEG)

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel